Fig. 5

The anti-HCC effect of brassicasterol and sorafenib on HBV + and HBV- HCC cells. HBV- HCC cell line HepG2 and HBV + HCC cell line HepG2.215 were incubated with increasing doses of A brassicasterol or B sorafenib for 48 h and cell viability was assessed by MTT assay. Data shown are mean ± SD of three independent experiments